Two Big Factors Hurting Biotech ETFs | Page 2 of 2 | ETF Trends

Observers argue that the longer protection period in the U.S. compared to foreign trading partners would lead to greater pressure at home.

“If you see too much of a price discrepancy (between the United States and trade partners), at some point you’re going to see a push back,” Steve Brozak, president of WBB Securities which focuses on smaller biotechs, told Reuters.

iShares Nasdaq Biotechnology ETF

For more information on the biotech sector, visit our biotechnology category.

Max Chen contributed to this article.